PubMed

Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.

Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Ehlers MR, Egan JM, Elahi D.

Diabetes Care. 2003 Mar;26(3):837-42.PMID: 12610046 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

Diabetes Care. 1996 Jun;19(6):580-6.PMID: 8725855 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.

Egan JM, Meneilly GS, Habener JF, Elahi D.

J Clin Endocrinol Metab. 2002 Aug;87(8):3768-73.PMID: 12161508 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.

Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Elahi D.

J Gerontol A Biol Sci Med Sci. 2001 Nov;56(11):M681-5.PMID: 11682575 [PubMed - indexed for MEDLINE]Related articles

Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.

Ryan AS, Egan JM, Habener JF, Elahi D.

J Clin Endocrinol Metab. 1998 Jul;83(7):2399-404.PMID: 9661618 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

Diabet Med. 1998 Nov;15(11):937-45.PMID: 9827848 [PubMed - indexed for MEDLINE]Related articles

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.

J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903.PMID: 14557471 [PubMed - indexed for MEDLINE]Related articlesFree article

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.

Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D.

Diabetes Care. 2003 Oct;26(10):2835-41.PMID: 14514588 [PubMed - indexed for MEDLINE]Related articlesFree article

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

Diabetes Care. 1998 Nov;21(11):1925-31.PMID: 9802745 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.

Diabetologia. 1993 Aug;36(8):741-4.PMID: 8405741 [PubMed - indexed for MEDLINE]Related articles

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

Diabetologia. 1996 Dec;39(12):1546-53.PMID: 8960841 [PubMed - indexed for MEDLINE]Related articles

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.

Diabetes Care. 2000 Jun;23(6):807-12.PMID: 10841001 [PubMed - indexed for MEDLINE]Related articlesFree article

GLP-1 does not not acutely affect insulin sensitivity in healthy man.

Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O.

Diabetologia. 1996 Oct;39(10):1227-32.PMID: 8897012 [PubMed - indexed for MEDLINE]Related articles

Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes.

Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D.

Diabetes Care. 2001 Nov;24(11):1951-6.PMID: 11679463 [PubMed - indexed for MEDLINE]Related articlesFree article

Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.

Exp Clin Endocrinol Diabetes. 1998;106(2):103-7.PMID: 9628239 [PubMed - indexed for MEDLINE]Related articles

Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes.

Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, Holst JJ, Rizza RA.

Diabetes. 2001 Mar;50(3):565-72.PMID: 11246876 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.

Diabetes. 1996 Nov;45(11):1524-30.PMID: 8866556 [PubMed - indexed for MEDLINE]Related articles

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.

J Clin Invest. 1993 Jan;91(1):301-7.PMID: 8423228 [PubMed - indexed for MEDLINE]Related articlesFree article

Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.

Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 2001 Apr;24(4):720-5.PMID: 11315837 [PubMed - indexed for MEDLINE]Related articlesFree article